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ABSTRACT
Objectives: To explore utilisation patterns of asthma
medication before, during and after pregnancy as
recorded in seven European population-based
databases.
Design: A descriptive drug utilisation study.
Setting: 7 electronic healthcare databases in Denmark,
Norway, the Netherlands, Italy (Emilia Romagna and
Tuscany), Wales, and the Clinical Practice Research
Datalink representing the rest of the UK.
Participants: All women with a pregnancy ending in a
delivery that started and ended between 2004 and
2010, who had been present in the database for the
year before, throughout and the year following
pregnancy.
Main outcome measures: The percentage of
deliveries where the woman received an asthma
medicine prescription, based on prescriptions issued
(UK) or dispensed (non-UK), during the year before,
throughout or during the year following pregnancy.
Asthma medicine prescribing patterns were described
for 3-month time periods and the choice of asthma
medicine and changes in prescribing over the study
period were evaluated in each database.
Results: In total, 1 165 435 deliveries were identified.
The prevalence of asthma medication prescribing
during pregnancy was highest in the UK and Wales
databases (9.4% (CI95 9.3% to 9.6%) and 9.4% (CI95
9.1% to 9.6%), respectively) and lowest in the
Norwegian database (3.7% (CI95 3.7% to 3.8%)). In
the year before pregnancy, the prevalence of asthma
medication prescribing remained constant in all
regions. Prescribing levels peaked during the second
trimester of pregnancy and were at their lowest during
the 3-month period following delivery. A decline was
observed, in all regions except the UK, in the
prescribing of long-acting β-2-agonists during
pregnancy. During the 7-year study period, there were
only small changes in prescribing patterns.
Conclusions: Differences were found in the
prevalence of prescribing of asthma medications
during and surrounding pregnancy in Europe. Inhaled
β-2 agonists and inhaled corticosteroids were,
however, the most popular therapeutic regimens in all
databases.
INTRODUCTION
Asthma is a common chronic respiratory
disease and maternal asthma, particularly
poorly controlled asthma, has been asso-
ciated with a number of adverse maternal
and pregnancy outcomes, including pre-
eclampsia, low birth weight, small for gesta-
tional age and preterm delivery.1 2 To
achieve good disease control and normal
lung function, women who are pregnant or
considering becoming pregnant are gener-
ally recommended to continue taking their
asthma medications, as the maternal and
fetal risks associated with uncontrolled
asthma are greater than the risks from using
asthma medications.3 4 Some studies have
demonstrated an increased risk of speciﬁc
major congenital malformations following
ﬁrst trimester exposure to asthma medica-
tions, but at present there is a degree of
Strengths and limitations of this study
▪ This study captured over 1.1 million pregnancies
from seven regions of Europe.
▪ Over 65 000 deliveries were included where the
woman received a prescription for an asthma
medication during pregnancy.
▪ Prescription data were recorded independently
by the prescriber or dispensing pharmacist,
removing maternal recall bias.
▪ In many people, the symptoms of asthma are
intermittent. While the date of prescribing or dis-
pensing is accurate, this is not necessarily
entirely consistent with the date of medicine use,
particularly with short-acting β-2-agonists pre-
scribed for symptom relief.
▪ An absence of data on indication for prescribing
was a limitation when investigating the use of
oral glucocorticoids to treat more severe asthma,
as these products can be prescribed to treat a
number of other conditions, including inflamma-
tory bowel disease and rheumatoid arthritis.
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uncertainty surrounding the effects of treatment versus
the effects of the disease itself.5–8 Asthma is initially
managed with short-acting β-2-agonists (SABAs) for
symptom relief in the case of reasonably well-controlled
disease and with a step-up approach when disease
control becomes reduced, with the addition of inhaled
corticosteroids (ICS) and other medications to prevent
and reduce inﬂammation of the airways.3 4 Studies
evaluating the course of asthma symptoms during preg-
nancy have shown that approximately one-third of
women ﬁnd their symptoms improve, one-third get
worse and one-third remain the same.9 10
The prevalence of asthma during pregnancy in
Europe has been estimated at between 4% and 8%,10–12
making it one of the most common, potentially serious,
medical complications in pregnancy.13 Estimates of
asthma prevalence during pregnancy vary by geographic
location, study setting, deﬁnition of asthma and time
period.10 11 14–16 The overall prevalence of prescribed
antiasthma therapy during pregnancy has been reported
for the UK,10 Sweden,17 Norway18 and the
Netherlands,16 but for many other regions of Europe it
is unknown and few studies have looked at the preva-
lence of prescribing of individual classes of asthma
medicine. This study aimed to describe the extent and
nature of asthma medication prescribing, during preg-
nancy and in the year before and after pregnancy,
between 2004 and 2010, using data from population-
based electronic healthcare databases in Europe. This
study forms part of EUROmediCAT, a Seventh
Framework Programme study funded by the European
Commission that aims to make more systematic use of
electronic healthcare databases in combination with the
EUROCAT congenital anomaly registry data19 for repro-
ductive safety evaluation.
METHODS
Setting
Seven population-based electronic healthcare databases,
which captured data on prescriptions and pregnancies,
contributed to the study; two in Italy (Tuscany20/Emilia
Romagna21), two in the UK (the Secure Anonymised
Information Linkage (SAIL) Databank in Wales22 23 and
the UK-wide Clinical Practice Research Datalink
(CPRD)24 with data from Wales excluded), and one
each in Denmark,25–27 the Netherlands28 and
Norway29 30 (see online supplementary table S1). A
more detailed description of the databases can be found
elsewhere.31 Where multiple databases were linked, such
as in Denmark, where data from the Danish National
Patient Register were linked to the Danish Prescription
Registry, for the remainder of this paper these linked
databases will be referred to as a single database.
Data extraction
A common protocol was implemented across databases.
All pregnancies were identiﬁed that started and ended
between 1 January 2004 and 31 December 2010 (except
for Denmark and Norway where inclusion dates were 1
January 2004 to 31 December 2009 and 1 January 2005
to 31 December 2010, respectively). Pregnancies were
eligible for the study if they ended in a delivery (live or
stillbirth) and the woman had been contributing data to
the database capturing prescription data, throughout
pregnancy and for a full year before the start of preg-
nancy and following delivery. Women were able to con-
tribute more than one pregnancy to the study. For each
eligible delivery, a best estimate of the ﬁrst day of the
last menstrual period was calculated as summarised in
online supplementary table S1.
All prescriptions for an asthma medication recorded
in the databases during the study period were identiﬁed.
In the UK databases, this included prescriptions issued
and in the non-UK databases this included only prescrip-
tions actually dispensed. None of the databases captured
asthma medications given directly to the patient during
a hospital stay. In Denmark, Norway and the
Netherlands, all asthma medication dispensed from a
pharmacy was captured, regardless of who prescribed
the medication and where the prescription was made. In
the UK databases, prescriptions initiated by a specialist
in a hospital outpatient department and private pre-
scriptions were rarely recorded; these numbers were
likely to be small as most subsequent repeat prescribing
will have been undertaken in primary care and private
practice is limited. In Italy, only prescriptions reim-
bursed by the Italian healthcare system were captured;
this included all reimbursed prescriptions regardless of
whether they were prescribed by a general practitioner
(GP) or a specialist who was an employee of the health-
care system. Asthma medications identiﬁed within the
databases included all SABA, long-acting β-2-agonists
(LABAs), ICS, combined β-2-agonists and inhaled ster-
oids in a ﬁxed-dose combination, leukotriene receptor
antagonists, cromoglicate and related therapy, antimus-
carinic bronchodilators and theophylline. These were
deﬁned as products with an Anatomical Therapeutic
Chemical (ATC) classiﬁcation code starting R03.
Prescriptions for oral glucocorticoids (ATC code
H02AB), potentially used to treat an asthma exacerba-
tion, were also identiﬁed. Since oral glucocorticoids can
be prescribed for conditions other than asthma, only
those prescribed in a 3-month time period during which
an asthma medication was also prescribed were eligible
for inclusion.
Analyses
The percentage of pregnancies where the women
received a prescription for an asthma medication in
each of the databases was calculated for the year leading
up to pregnancy, during pregnancy and the year follow-
ing pregnancy. Prescribing patterns were described for
each pregnancy trimester and for 3-month time periods
during the years before and after pregnancy. For each
class of asthma medication, the speciﬁc products most
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frequently prescribed were compared between regions.
Changes in prescribing over calendar time were also
described and compared. Sensitivity analyses were
carried out restricting the analyses to those deliveries
where the woman received a minimum of two prescrip-
tions for an asthma medicine during the 33-month time
period of interest.
RESULTS
Within the seven databases, 1 165 435 deliveries were
identiﬁed (table 1). The mean maternal age at the start
of pregnancy was highest in Emilia Romagna and lowest
in Wales (32.3 and 27.7 years, respectively) (table 1).
The mean maternal age in all of the regions did not
vary substantially between those who received and those
who did not receive a prescription for an asthma medi-
cine. The prevalence of asthma medication prescribing
during pregnancy was highest in the UK and Wales data-
bases (9.4% (CI95 9.3% to 9.6%) and 9.4% (CI95 9.1%
to 9.6%), respectively) and lowest in the Norwegian data-
base (3.7% (CI95 3.7% to 3.8%)).
During the year before pregnancy, the prevalence of
asthma medication prescribing was relatively constant in
all regions (ﬁgure 1A). In Italy and Norway, a reduction
in prescribing was observed during the ﬁrst trimester of
pregnancy. During pregnancy, prescribing levels peaked
during the second trimester with the largest increases
being observed in the UK/Wales. Prescribing was at its
lowest during the 3-month period following delivery and
then gradually increased, returning towards prepreg-
nancy levels, during the remainder of the year following
delivery. Of those who received a prescription for an
asthma medication in the year before, during and/or
the year after pregnancy, approximately 30% in the
Netherlands, Wales and the rest of the UK received only
a single prescription during this 33-month time period;
in Denmark, it was 39%, Norway 45% and in Emilia
Romagna it was as high as 50%. Table 2 and ﬁgure 1B
show the prevalence of asthma medication prescribing
in each of the regions restricted to pregnancies where
the woman was issued/dispensed at least two prescrip-
tions for an asthma medicine during the 33-month time
period. Inhaled SABAs and ICS were the products most
commonly prescribed to women who received only a
single prescription (data not shown).
The prescribing prevalence of SABAs in each of the
3-month time periods was lowest in Tuscany and highest
in the UK databases (ﬁgure 2). In the UK, approxi-
mately 90% of women who received a prescription for
an asthma medication during pregnancy received a pre-
scription for a SABA, whereas in Denmark and Norway
it was approximately 75% and in Italy it was 26%. These
percentages were not dissimilar to those during the year
before pregnancy. In all regions, with the exception of
Denmark where terbutaline was the most popular, salbu-
tamol accounted for the majority of SABA prescriptions
(ﬁgure 2). SABAs in a ﬁxed-dose combination with an
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ICS were rarely prescribed in all regions, with the Italian
databases having the highest prescribing prevalence. In
the UK, the SABA prescribing prevalence increased
during the second trimester of pregnancy and was
approximately 25% higher than during the ﬁrst
trimester.
Norway had the lowest prescribing prevalence of ICS
and the UK had the highest (ﬁgure 3). Of women who
received a prescription for an asthma medication during
one of the pregnancy trimesters, approximately 50% in
Norway, 60% in the UK and Denmark and 89% in
Emilia Romagna received a prescription for an ICS
during pregnancy. Italy was the only region where pre-
scribing of ICSs was more common than the prescribing
of SABAs. In the UK/Wales and Italian databases, beclo-
metasone was the most commonly prescribed ICS,
whereas in Denmark it was budesonide and in Norway
beclometasone and budesonide were equally prescribed
(ﬁgure 3). In the Netherlands, the prevalence of beclo-
metasone prescribing during pregnancy was almost
double the prevalence observed before and after preg-
nancy, with the increase coinciding with a reduction in
the prescribing of ﬂuticasone and other ICS in a ﬁxed-
dose combination with a LABA. Norway was the only
region where the prevalence of prescribing of ICS in a
ﬁxed-dose combination with a LABA was higher than
the prescribing of ICS products not as part of a ﬁxed-
dose combination.
During pregnancy, evidence of a reduction in the pre-
scribing of LABAs, both alone and as part of a ﬁxed-
dose combination, was observed in Norway, the
Netherlands and Italy (ﬁgure 4). In Norway and Italy,
prescribing was approximately 50% lower during the
second trimester of pregnancy compared with the
3-month period prior to the start of pregnancy; in the
Netherlands, it was approximately 65% lower. Of those
who received a prescription for a LABA during preg-
nancy, between 75.2% in Tuscany and 86.5% in Norway
received it in a ﬁxed-dose combination with an ICS.
Salmeterol in a ﬁxed-dose combination was the most
commonly prescribed LABA product in the UK, Italy
and the Netherlands, while in Denmark it was formo-
terol in combination with an ICS and in Norway both
formoterol and salmeterol in ﬁxed-dose combinations
were prescribed to the same degree. This was not sub-
stantially different from the therapeutic pattern
observed in non-pregnant women during prepregnancy.
The prescribing of other asthma medications was low
in all regions and lowest in Denmark and Norway
(ﬁgure 5). Cromones were rarely prescribed, although
Figure 1 Prevalence of asthma
medication prescribing in women
with a delivery, between 2004
and 2010, where the woman
received (A) ≥1 prescription for
an asthma medication during ≥1
of the time periods of interest and
(B) ≥2 prescriptions for an
asthma medication during the
entire time period of interest.
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the number of women receiving a prescription in
Norway increased to 51 during the ﬁrst trimester of
pregnancy compared with 17 during the 3-month
period before pregnancy. The percentage of deliveries
where the mother received a prescription for a leuko-
triene receptor antagonist during pregnancy ranged
from 0.04% (CI95 0.03% to 0.04%) in Norway to 0.14%
(CI95 0.11% to 0.17%) in Wales, with all regions showing
a decline in prescribing during the latter trimesters. No
prescriptions for an anticholinergic were dispensed
during the time period of interest in Denmark and the
highest level of prescribing of these during pregnancy
was observed in the Netherlands, with 0.16% (CI95
0.10% to 0.23%) of women receiving a prescription.
Prescribing of oral glucocorticoids was considerably
higher in the UK and Italy than other regions, although
in all databases the levels of prescribing declined during
pregnancy and increased steadily in the year following
delivery. Prednisolone was the most commonly pre-
scribed oral corticosteroid in all regions.
During the 7-year study period, there were only small
changes in prescribing patterns. In Denmark, Norway
and the UK, the prescribing prevalence of LABAs in a
ﬁxed-dose combination with an ICS during pregnancy
was found to increase (0.7–1.1%, 1.1–1.3% and 1.1–
1.9%, respectively) while the prescribing of LABAs not
in a ﬁxed-dose combination was found to decline. In the
UK, a small decline in the prescribing of ICS not in
combination with a β-agonist was observed between 2004
and 2009 (from 4.5% (CI95 4.2% to 4.7%) to 3.8% (CI95
3.6% to 4.0%) of all pregnancies), while in Denmark
there was evidence of a small decline in SABA
prescribing.
DISCUSSION
Main findings
This study found variations in the prevalence of asthma
medication prescribing and the speciﬁc products most
commonly prescribed to women before, during and
after pregnancy in different regions of Europe. Changes
in prescribing were observed during pregnancy, with a
peak in prescribing in the second trimester, after which
prescribing declined until 4–6 months after delivery.
The prescribing of asthma medications was considerably
higher in the UK/Wales and Emilia Romagna than in
other regions; for the UK/Wales, the differences may be
accentuated because these databases captured all pre-
scriptions issued, while the other databases captured
only those actually dispensed.
Strengths and limitations
This study captured over 65 000 deliveries, between 2004
and 2010, where the woman received a prescription for
an asthma medication during her pregnancy.
Prescription information was recorded independently by
the prescriber or pharmacist, removing maternal recall
bias. No data, however, were available on whether the
Ta
b
le
2
P
er
ce
nt
ag
e
of
de
liv
er
ie
s
be
tw
ee
n
20
04
an
d
20
10
re
st
ric
te
d
to
w
om
en
w
ho
re
ce
iv
ed
≥
2
pr
es
cr
ip
tio
ns
fo
r
an
as
th
m
a
m
ed
ic
at
io
n
in
th
e
ye
ar
be
fo
re
pr
eg
na
nc
y,
du
rin
g
pr
eg
na
nc
y
or
th
e
ye
ar
fo
llo
w
in
g
pr
eg
na
nc
y
N
u
m
b
er
o
f
el
ig
ib
le
d
el
iv
er
ie
s
in
en
tir
e
co
h
o
rt
M
ea
n
m
at
er
n
al
ag
e
at
p
re
g
n
an
cy
st
ar
t
fo
r
en
tir
e
co
h
o
rt
A
n
as
th
m
a
m
ed
ic
at
io
n
p
re
sc
ri
p
tio
n
d
u
ri
n
g
O
n
e
ye
ar
b
ef
o
re
p
re
g
n
an
cy
A
n
y
o
f
th
e
p
re
g
n
an
cy
tr
im
es
te
rs
O
n
e
ye
ar
fo
llo
w
in
g
p
re
g
n
an
cy
C
o
u
n
tr
y/
re
g
io
n
N
Y
ea
rs
S
D
*
N
P
er
ce
n
t
(9
5%
C
I)
N
P
er
ce
n
t
(9
5%
C
I)
N
P
er
ce
n
t
(9
5%
C
I)
D
en
m
ar
k†
32
0
84
6
30
.0
(4
.9
)
12
59
3
3.
9
(3
.9
to
4.
0)
10
65
0
3.
3
(3
.3
to
3.
4)
10
90
0
3.
4
(3
.3
to
3.
5)
Ita
ly
—
T
us
ca
ny
15
7
91
6
31
.8
(4
.9
)
75
51
4.
8
(4
.7
to
4.
9)
49
30
3.
1
(3
.0
to
3.
2)
71
13
4.
5
(4
.4
to
4.
6)
Ita
ly
—
E
m
ili
a
R
om
ag
na
12
8
42
9
32
.3
(4
.9
)
98
95
7.
7
(7
.6
to
7.
9)
68
31
5.
3
(5
.2
to
5.
4)
94
53
7.
4
(7
.2
to
7.
5)
N
or
w
ay
‡
30
1
82
0
29
.7
(5
.1
)
10
01
6
3.
3
(3
.3
to
3.
4)
79
08
2.
6
(2
.6
to
2.
7)
80
80
2.
7
(2
.6
to
2.
7)
T
he
N
et
he
rla
nd
s
14
60
7
30
.2
(4
.8
)
75
1
4.
9
(4
.6
to
5.
2)
60
1
4.
1
(3
.8
to
4.
4)
53
8
3.
7
(3
.4
to
4.
0)
U
K
*
18
2
92
0
30
.2
(6
.1
)
14
77
3
8.
1
(8
.0
to
8.
2)
14
40
2
7.
9
(7
.8
to
8.
0)
14
58
2
8.
0
(7
.8
to
8.
3)
W
al
es
58
10
6
27
.7
(6
.1
)
48
58
8.
4
(8
.1
to
8.
6)
46
17
8.
0
(7
.7
to
8.
2)
46
83
8.
1
(3
.3
to
3.
5)
T
ot
al
ac
ro
ss
co
un
tr
ie
s
1
16
5
43
5
*E
xc
lu
di
ng
W
al
es
to
av
oi
d
du
pl
ic
at
io
n
of
pr
eg
na
nc
ie
s
in
th
e
W
el
sh
S
ec
ur
e
A
no
ny
m
is
ed
In
fo
rm
at
io
n
Li
nk
ag
e
(S
A
IL
)
D
at
ab
an
k.
†
20
04
–
20
09
.
‡
20
05
–
20
10
.
S
D
,s
ta
nd
ar
d
de
vi
at
io
n.
Charlton RA, et al. BMJ Open 2016;6:e009237. doi:10.1136/bmjopen-2015-009237 5
Open Access
Figure 2 Prevalence of prescribing of short-acting β-2-agonists (SABAs) in the year before, during and after pregnancy in
women with a live or stillbirth during 2004–2010 for women prescribed ≥1 prescription for an asthma medication during ≥1 of the
time periods of interest.
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Open Access
Figure 3 Prevalence of prescribing of ICS in the year before, during and after pregnancy in women with a live or stillbirth during
2004–2010 for women prescribed ≥1 prescription for an asthma medication during ≥1 of the time periods of interest (ICS,
inhaled corticosteroid; LABA, long-acting β-2-agonist; SABA, short-acting β-2-agonist).
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Figure 4 Prevalence of prescribing of long-acting β-2-agonists (LABAs) in the year before, during and after pregnancy in
women with a live or stillbirth during 2004–2010 for women prescribed ≥1 prescription for an asthma medication during ≥1 of the
time periods of interest.
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women took the medication and whether it was adminis-
tered as instructed. The often intermittent nature of
asthma symptoms and the fact that some treatments can
be used on an ‘as needed’ basis makes determining the
precise timing of exposure difﬁcult in electronic health-
care databases. In the UK databases, data were based on
Figure 5 Prevalence of prescribing of other asthma medications in the year before, during and after pregnancy in women with a
live or stillbirth during 2004–2010 for women prescribed ≥1 prescription for an asthma medication during ≥1 of the time periods
of interest.
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prescriptions issued, whereas in other regions it was pre-
scriptions dispensed. It is possible that some women who
are issued prescriptions may not get them dispensed.
However, even if we take a conservative estimate and
assume that 25% of prescriptions issued in the UK data-
bases were not dispensed, the levels of asthma prescrib-
ing during pregnancy would still be higher in the UK/
Wales than in all other regions, with the exception of
Emilia Romagna. This study did not account for pre-
scriptions issued during one 3-month time period that
could have continued to be taken during the following
3-month time period. This will have resulted in an
underestimation of exposure during some time periods,
especially as women may use inhalers for a long time
after they are prescribed. Some women may also have
several inhalers for a product issued in a single prescrip-
tion and women may have multiple inhalers of the same
product in use at the same time. The study period for
which data were available did vary between databases
and it is possible that these small differences in calendar
time may have inﬂuenced the results and could explain
some of the variations observed; however, for those
countries contributing data for the entire study period,
only small changes in prescribing patterns by calendar
time were observed.
An absence of data on indication for prescribing was a
limitation when investigating the use of oral glucocorti-
coids to treat more severe asthma and asthma exacerba-
tion, as these products can be prescribed to treat a
number of other conditions. This study attempted to
reduce the impact of this by only including oral gluco-
corticoid prescriptions if they were issued during the
same 3-month period as an asthma medication; it is likely,
however, that some misclassiﬁcation will still have
occurred. In addition, some women will not have needed
to take the oral glucocorticoids at the time of issue but
will have been prescribed them in advance so that they
had them available for when they experienced an exacer-
bation in the future. None of the databases captured pre-
scriptions issued during a hospital stay or a visit to an
accident and emergency department and this may have
led to an underestimate of the use of oral glucocorticoids
to treat asthma exacerbations. An absence of data on the
indication for prescribing of medications was also a limi-
tation when trying to interpret and provide explanations
for the differences observed in prescribing practices. The
large percentage of women receiving only a single pre-
scription in some regions may imply that some products
may be being prescribed for bronchoconstriction in asso-
ciation with acute bronchitis or other respiratory tract
infections. Inhaled SABAs and ICS were the products
most commonly prescribed to women who received only
a single prescription and in these cases they are unlikely
to have been for a chronic condition. It is also possible
that some women are started on an inhaled SABA or ICS
to see if it has any effect on the symptoms and if there is
no effect, the treatment is discontinued and it is con-
cluded that the woman was not suffering from asthma.
Comparison with the literature
The UK prescribing prevalence of asthma medications
during pregnancy in this study was found to be slightly
higher than that reported by a previous study looking at
the prevalence of treated asthma using data from the
CPRD (9.4% vs 8.3%).10 The previous study had
required women to have evidence of an asthma diagno-
sis in addition to at least one prescription or a minimum
of six prescriptions to be eligible for inclusion in the
study, and this is likely to explain some of the difference
observed. Trends and levels of overall asthma medication
prescribing in the Netherlands and Norway were in line
with those reported elsewhere for studies looking at a
similar time period and using the same data sources
(5.1% vs 4.5% during pregnancy in the Netherlands and
1.7% vs 1.7% during the ﬁrst trimester in Norway).16 18
The Norwegian study, however, had not reported on the
prescribing prevalence during the entire pregnancy and
on the level of prescribing of speciﬁc classes of asthma
medications. In Denmark, a large cohort study based on
maternal self-reporting, rather than prescription data,
had reported that 6.2% of women suffered from asthma
during pregnancy between 1996 and 2002, which was
higher than the 4.4% (CI95 4.3% to 4.4%) who had
received a prescription during the slightly later time
period of our study.11 To the best of our knowledge, this
is the ﬁrst study to report on the prevalence of asthma
medication prescribing during pregnancy in Italy.
Interpretation
The variation observed in the levels of prescribing may
to some extent reﬂect differences in the prevalence of
asthma in the different regions. The World Health
Survey conducted by the WHO has reported country-
speciﬁc estimates of doctor diagnosed asthma preva-
lence, at any time, in individuals aged 18–44 years. This
study found a considerably lower prevalence of asthma
in Italy (6.0%) compared with the other regions in our
study: 9.5% in Denmark, 11.1% in Norway, 15.2% in the
Netherlands and 17.6% in the UK.32 Variations may also
be explained by differences in exposure to allergens,
infections, air pollution and climate, as well as the cost
of individual medications and different attitudes to pre-
scribing. Unfortunately, data on these variables were not
available within the majority of databases and could not
be evaluated as part of this study. Variations in preva-
lence and these variables may also explain the within-
country regional prescribing differences observed
between the two Italian databases, with the Italian
National Survey data33 demonstrating geographic vari-
ation in asthma prevalence (5.3% vs 8.4% in Tuscany vs
Emilia Romagna, respectively). Hospital admission data
for asthma exacerbations in Italy support our ﬁndings,
with higher hospital admissions observed in Emilia
Romagna than Tuscany,34 as well as higher costs asso-
ciated with the diagnostic label ‘bronchitis (asthmatic)/
asthma’.35 The differences in prescribing prevalence
between Tuscany and Emilia Romagna and the
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representativeness of the two regions do not permit the
extrapolation of the results to the rest of Italy. The ﬁnd-
ings of our study also demonstrated a peak in asthma
medication prescribing during the second trimester in
all regions. This may be explained by the ﬁndings of a
systematic review that concluded that a worsening of
asthma symptoms is most likely during the latter trime-
sters with a peak in the sixth month of gestation and an
improvement during the last 4 weeks of pregnancy,36
which may also explain some of the lower levels of pre-
scribing observed shortly after pregnancy. It is also pos-
sible that women are informed of the importance of
well controlled asthma when visiting their GP during
their pregnancy, and they are therefore more likely to
request and use the required prescriptions during the
second trimester than they were during the early stages
of pregnancy. Women may also, to some extent, feel
more reassured about taking their asthma medicines
once the critical period of organogenesis during the
ﬁrst trimester of pregnancy has passed.
In all regions, the prescribing guidelines advised that
treatment for asthma during pregnancy should be the
same as that for other groups of patients and that the
risks associated with poorly controlled asthma were
greater than those posed by conventional asthma medica-
tions.4 37–41 There was general agreement that SABAs
were not teratogenic, with salbutamol and terbutaline
being the recommended ﬁrst choice. In Italy, however,
the possibility of increased risks of maternal and neonatal
transitory hypoglycaemia, maternal and fetal tachycardia,
acute heart failure, pulmonary oedema and maternal
death were listed in relation to salbutamol and the guide-
lines stated that the manufacture advised to avoid during
pregnancy unless the potential beneﬁt outweighs the
risk.37 The advice from the manufacturer and the risk of
a number of maternal and fetal outcomes were not
reported in the guidelines of the other regions, and it is
possible that this may, in part, explain the lower levels of
SABA prescribing in Italy than the other regions; these
risks are, however, largely thought to be associated with
medication when used as an infusion and not for inhaled
medications used at a normal dose.
All guidelines advised that there was no need to stop
ICS during pregnancy.4 37–39 41 During the study period,
budesonide was the only ICS that had the more favour-
able Food and Drug Administration (FDA) pregnancy
category B, while all others had an FDA pregnancy cat-
egory C, indicative of the fact that animal reproduction
studies had shown an adverse effect on the fetus and
there were no adequate and well-controlled studies in
humans.42 Norway41 and Italy37 were the only countries,
however, where the guidelines recommended budeso-
nide as the ICS of choice and Denmark39 was the only
region where budesonide was found to be the ICS most
commonly prescribed. In Italy, despite the guidelines
recommending budesonide, beclometasone was by far
the most commonly prescribed ICS. The Italian guide-
lines37 on beclometasone also stated that the
manufacturer recommends avoiding its use during the
ﬁrst trimester; although a small reduction was observed
during this time period, it was still quite commonly pre-
scribed. It is possible that other factors, including the
cost of different products, may inﬂuence prescribing
practices in the different regions, but this study was not
able to investigate this.
The UK guidelines were the only ones to specify that
LABAs should be used with an ICS and ideally as part of
a combination product.4 It was stated that although little
information is available on the safety of combination
products, there is no reason, in this instance, to think
that the products would be more harmful in combin-
ation than when given separately. In the Danish guide-
lines, no concerns were raised about the use of LABAs,39
and the UK guidelines referenced evidence from pre-
scription event monitoring to suggest that salmeterol
was safe in pregnancy.4 In Norway, it was advised that the
older and better known LABAs should be used before
the newer ones and this study found salmeterol and for-
moterol to be the most popular and prescribed products
in equal measures.41 In the Netherlands, the guidelines
on LABAs differed from other regions, with the
emphasis being put on the lack of information relating
to their safety and guidance from the Dutch College of
General Practitioners advising against the use of these
medications in pregnancy.38 The differences in prescrib-
ing guidelines relating to LABAs are likely to explain
some of the variations observed between regions. Our
study observed a sharp decline in the prescribing of
LABAs during pregnancy in the Netherlands, which is in
line with the guidelines and has also been observed in a
Dutch study by Zetstra-van der Woude et al.16 The
decline in the prescribing of LABAs during pregnancy,
observed in all regions except the UK, indicates that
clinicians and pregnant women may worry about using
these rather new inhaled medications during pregnancy,
as there are currently few published studies reporting on
their safety.
The limited information on the safety of leukotriene
receptor antagonists was acknowledged within all guide-
lines, with a general consensus that they should not be
started during pregnancy but could be continued in
women who were using them to successfully control
their asthma before pregnancy; all regions in our study
saw some decline in the level of their prescribing during
pregnancy. For oral glucocorticoids, several of the guide-
lines mentioned the possibility of an increased risk of
cleft lip/palate if used during the ﬁrst trimester of preg-
nancy, and our study observed a decline in their use
during pregnancy in all regions. In Denmark, the UK
and the Netherlands, it was stated that any well indicated
treatment should be initiated and not withheld during
pregnancy as the advantages of well controlled asthma
would outweigh any associated risk to the fetus.4 38 39 In
Denmark and the Netherlands, it was recommended
that these were prescribed at the lowest dose and for the
shortest time period. The low prescribing levels of oral
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asthma medications in general in all regions and the
decline observed during pregnancy are reassuring, as
treatment guidelines focus on inhaled medications and
recommend the addition of oral products only for
severe asthma.
CONCLUSION
This study identiﬁed differences in the percentage of
women who received a prescription for an asthma medi-
cation during and surrounding pregnancy in different
regions of Europe. Differences were also observed in
relation to the speciﬁc products that were most com-
monly prescribed; however, no major differences were
observed in the treatment in general with inhaled β-2
agonists and ICS being prescribed to the majority of
women.
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